Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Phase Distribution

Ph phase_2

33%

Ph not_applicable

33%

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (33.3%)

Phase 41 (33.3%)

N/A1 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_2

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830

completedphase_4

Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

NCT02752191

completednot_applicable

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

NCT01431300

Clinical Trials (3)

Showing 3 of 3 trials

NCT00375830Phase 2

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Completed

NCT02752191Phase 4

Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

Completed

NCT01431300Not Applicable

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3